In addition, EVO enhanced the efficacy of radiation therapy by significantly inhibiting the cell cycle progression and growth in human gastric cancer BGC-823 cells in vitro and markedly suppressing the tumor growth of BGC-823 xenografts in vivo, and the anticancer effect of EVO was related to the downregulation of the Her2/AkT/Bcl-2 signaling pathway (Hu C. et al., 2016). Here, BCL2 is linked to neoplasm.